drugset / Trial / NCT00002231

Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers

NCT00002231 ↗

Phase 1 Completed Wyeth-Lederle Vaccines
Open-labelPrevention

Summary

The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject GENEVAX-HIV Vaccine — Intramuscular